Lifecare is committed to improving the lives of people and pets with diabetes. It is developing the next-generation of miniaturized and implantable nanobiosensors for correct and continuous monitoring of glucose and other biomarkers to the market. The company’s spin-off entity Lifecare Chemistry Ltd was founded to enhance research collaboration and secure ownership of its improved analyte-specific chemical receptor developments.

Carbometrics is striving to improve diabetes patient care by enhancing technology for continuous glucose monitoring. The team aims to pave the way for a new class of highly-accurate sensors with its groundbreaking synthetic molecule that is both chemically stable and able to bind to glucose in the blood. This follows on from the work of exited startup Ziylo Ltd, which was Science Creates’ very first resident and acquired by Novo Nordisk in 2018.

Argonaute RNA is developing safe, reliable and targeted methods of temporarily silencing genes in different tissue cells. It does this via the proprietary modification of small interfering RNA (siRNA), using a novel stabilisation method to overcome previous obstacles to developing siRNA drugs for healthcare.

Scarlet Therapeutics is developing a proprietary platform that generates novel red blood cell-based therapeutics (tRBCs) to treat a wide range of diseases. Its technologies are underpinned by learnings from decades of research including the groundbreaking RESTORE clinical study run by NHS Blood and Transplant and the University of Bristol, investigating transfusion of lab-grown blood into patients. By generating tRBCs with high levels of therapeutic proteins from cell lines rather than from donated stem cells, Scarlet Therapeutics aims to address significant efficacy and manufacturing issues faced in the field.

CoED Biosciences is transforming human tissue separation for adoptive cell therapy and research purposes. Its Column of Expansion and Differentiation (CoED) device harnesses the power of chemotaxis and gravity to gently purify and extract immune cells from blood or tumour biopsies. The process preserves both the integrity and functionality of the tissues without the need for magnets or centrifugation, saving valuable time and resources.

STL is leveraging its deep sector expertise as a venture builder to unlock the true value of innovation. Working alongside a network of investors and service providers, its strategic commercialisation process helps its customers build IP-led businesses that are viable and sustainable. It does this by applying streamlined entrepreneurial capabilities, in-house engineering and end-to-end due diligence for ventures bringing new technologies to life from basic concept to prototype demonstration, enhancing their growth and scalability.